Optimize blood sampling conditions for PA screening

STEP 1 — Gather Information

• Record time of day, fasting status (≥8 h overnight fast), and patient posture (supine vs sitting) at blood draw.
• Note any recent food intake, caffeine, nicotine, or vigorous exercise that could influence aldosterone or renin.
• Document whether the sample was obtained in the sitting position at any time.

STEP 2 — Rule In / Rule Out

• Is the sample obtained in the sitting position (regardless of fasting or time of day)?
  • Yes → proceed to Step 3 (acceptable per guideline).
  • No → proceed to Step 3 (non‑ideal supine sample).

STEP 3 — Classify or Stratify

• Sitting sample: classify as acceptable for screening; no further stratification needed.
• Supine sample: classify as non‑ideal; assess fasting status and time of day:
  • If fasting and early morning → ideal (proceed with standard interpretation).
  • If non‑fasting or not early morning → suboptimal; flag for potential reduced sensitivity/specificity.

STEP 4 — Decide

• For acceptable (sitting) or ideal supine samples: apply standard screening cutoffs (ARR ≥ 200 or PAC/ARC ≥ 40 with PAC ≥ 60 pg/mL).
• For suboptimal supine samples: either repeat the draw under ideal conditions if clinically feasible, or proceed with screening while interpreting results with caution (consider borderline ARR/PAC values as provisionally positive and pursue individualized management).

Clinical Guardrails / Mimics / Pitfalls

• Do not rely solely on a non‑ideal supine sample to exclude PA; false‑negative risk increases.
• Avoid assuming sitting position eliminates all preanalytical influences; still control for recent meals, stress, and medications that affect renin.
• Do not ignore the preference for early‑morning supine fasting when it is readily obtainable; use it to maximize test accuracy.

Concrete Clinical Example

A 58‑year‑old hypertensive patient has blood drawn in the sitting position after a light breakfast. The clinician questions validity. According to the guideline, sitting sampling is acceptable; the sample is processed with ARR ≥ 200 and PAC ≥ 60 pg/mL cutoffs, and screening proceeds without repetition.

Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2022, https://www.jstage.jst.go.jp/article/endocrj/69/4/69_4_327/_article